Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
about
Update on the emerging role of telavancin in hospital-acquired infectionsThe role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.Oritavancin: A Long-Half-Life Lipoglycopeptide.Cyclodextrin complexes for treatment improvement in infectious diseases.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Evaluation of polymorphisms in pbp4 gene and genetic diversity in penicillin-resistant, ampicillin-susceptible Enterococcus faecalis from hospitals in different states in Brazil.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
P2860
Q28083522-3B243FB0-7DFB-44E7-9948-54E4BA65BC93Q34672655-FE672ED4-61DB-4A88-BCA6-6F4C7DC08D3FQ36439168-8F756224-D094-4E48-ACE7-2297828A8028Q38434265-5E5B97C9-D272-4502-8169-E56332F8744FQ38501664-5A0D1BB7-80A1-4D2B-A92D-64EFB65AB881Q38522574-D65AC171-586D-444A-8512-C638D04DEF42Q38646905-ADA39DD2-478A-416B-8466-70D4567CAF23Q40781790-B8739EC6-ACC5-41EE-8A54-205ABF984F7DQ41028154-4DA4718F-18CE-43DA-A3BB-BA13A525A9A7Q42073195-3219BFE2-487C-4AC6-9CCB-618AF4F03681Q42680740-A4C0A81A-8979-4B4F-97CB-25AFC40190F5
P2860
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Baseline activity of telavanci ...... susceptibility testing method.
@en
type
label
Baseline activity of telavanci ...... susceptibility testing method.
@en
prefLabel
Baseline activity of telavanci ...... susceptibility testing method.
@en
P2093
P2860
P356
P1476
Baseline activity of telavanci ...... susceptibility testing method.
@en
P2093
David J Farrell
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.04052-14
P407
P577
2014-10-27T00:00:00Z